Aktis Oncology, Inc.
Nasdaq: AKTSPharmaceutical Preparations · Entity-resolved by Clous
CIK0002035832
TickerAKTS
ExchangeNasdaq
SIC2834
StateDE
FY end12-31
Illustrative profile — live data lights up when a server API key is configured.
Key financials
RevenueFY2025
$416.16B
+6.4% YoY
Net IncomeFY2025
$104.9B
+11.9% YoY
Total AssetsFY2025
$371B
+1.6% YoY
EquityFY2025
$66B
+15.9% YoY
Shares OutstandingFY2025
14.84B
-1.8% YoY
Operating Cash FlowFY2025
$125B
+5.7% YoY
Market
Market
AKTSClose price
$24.09
Market cap
$1.29B
delayed EOD · as of 2026-06-18
Short interest & fails
Cost to borrow1.57%100K shares availablehard to borrow
Short-sale volume
FINRA Reg SHO · daily79.5%
short of total volume · 2026-06-18
2026-06-1879.5%
2026-06-1774.5%
2026-06-1694.6%
2026-06-1590.7%
2026-06-1278.9%
Fails-to-deliver
SEC CNS fails · semi-monthly1.17K
shares failed · 2026-05-28
2026-05-281.17K sh$19.92
2026-05-263.31K sh$20.34
2026-05-155.49K sh$19.50
2026-05-142 sh$19.53
2026-05-017.25K sh$18.75
Short volume (FINRA Reg SHO) · fails-to-deliver (SEC) · borrow fee (broker securities-lending feed) — via the Clous API.
| Concept | FY2023 | FY2024 | FY2025 | YoY | % rev |
|---|---|---|---|---|---|
| Revenue | $383.29B | $391.04B | $416.16B | +6.4% | 100% |
| Gross Profit | $169.15B | $180.68B | $196.42B | +8.7% | 47% |
| Operating Income | $114.3B | $123.22B | $133.9B | +8.7% | 32% |
| Net Income | $97B | $93.74B | $104.9B | +11.9% | 25% |
| Total Assets | $352.58B | $364.98B | $371B | +1.6% | 89% |
| Total Liabilities | $290.44B | $308.03B | $305B | -1.0% | 73% |
| Stockholders Equity | $62.15B | $56.95B | $66B | +15.9% | 16% |
| Cash & Equivalents | $29.97B | $29.94B | $32B | +6.9% | 8% |
| Operating Cash Flow | $110.54B | $118.25B | $125B | +5.7% | 30% |
| Shares Outstanding | 15.55B | 15.12B | 14.84B | -1.8% | — |
Get this entity — and 970.89K+ others — programmatically.
One clean JSON shape, resolved IDs, MCP-native. Query the same data behind this page.
GET /v1/entities?cik=0002035832